Arvinas is focused on developing new small molecules known as PROTACs
(PROteolysis TArgeting Chimeras) aimed at degrading disease-causing cellular proteins via proteolysis.
HL Ten years ago, the high lumen output for lights of this type averaged 65.
Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, has formed a strategic collaboration with Merck in which Arvinas' novel PROTAC
technology will be used to degrade target proteins with the goal of creating novel therapeutics.
This is said to be a significant goal because PROTAC
technology pushes these proteins to what Yale calls a cell's 'garbage disposal', which means that they could be destroyed.